The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2023 | Impact of prior BCMA-directed therapy on the efficacy of elranatamab in R/R multiple myeloma
Based on the pooled analysis of the MagnetisMM studies (MM-1: NCT03269136, MM-3: NCT04649359, MM-9: NCT05014412), Salomon Manier, MD, PhD, Lille Hospital University, Lille, France, discusses the efficacy of elranatamab for patients with relapsed/refractory (R/R) multiple myeloma who have been treated with B-cell maturation antigen (BCMA)-directed therapies. The study showed that overall, patients who had received prior BCMA therapy had lower response rates (RR) compared to patients who didn’t, and reported that patients treated with CAR-T therapy first had a higher overall response rate (ORR) than patients who received an antibody-drug conjugate (ADC) before treatment with elranatamab. This information supports the use of CAR-T prior to bispecific antibodies. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
